Drug Trial Radar · NCT04145440
Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)
Last checked: Nov 20, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Oct 15, 2019
Primary completion
Jan 19, 2022
Study completion Aug 2, 2022
Sponsor
- Lead sponsor
- HI-Bio, A Biogen CompanyIndustry
- Sponsor type
- Industry
- First posted
- Oct 30, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicentre study to characterize the safety and efficacy of the human anti-CD38 antibody MOR202 in adult subjects with in Anti-PLA2R Antibody Positive Membranous Nephropathy (newly diagnosed/relapsed/refractory)
Conditions
- Glomerulonephritis, Membranous
- antiPLA2R Positive
Interventions
MOR202Drug
Patients received 9 doses of MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing occured weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse EventsTime frame: Week 1 to Week 24
- Percentage of Participants With Adverse EventsTime frame: Week 1 to Week 24
Locations
45 sites in 9 countries. Site status is shown where the registry gives one.
North America Research Institute
Azusa, California
UCSF Medical Center
San Francisco, California
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California
University of Miami Division of Nephrology & Hypertension
Miami, Florida
GA Nephrology Associates
Lawrenceville, Georgia
Northwest Louisiana Nephrology Research
Shreveport, Louisiana
Kidney Care and Transplant Services of New England, PC
Springfield, Massachusetts
Mayo Clinic
Rochester, Minnesota
The Ohio State University Wexner Medical Center
Columbus, Ohio
MedResearch, Inc
El Paso, Texas
Texas Research Institute
Fort Worth, Texas
Western Health
Melbourne, Australia
St. George Hospital
Sydney, New South Wales, Australia
Royal Melbourne Hospital
Melbourne, Victoria, Australia
O.L.V. Ziekenhuis
Aalst, Belgium
C.H.U. Brugmann - Site Victor Horta
Brussels, Belgium
Universitair Ziekenhuis Brussels
Brussels, Belgium
Cliniques Universitaires Saint-Luc
Brussels, Belgium
UZ Leuven
Leuven, Belgium
CHU de Liège
Liège, Belgium
Groupe Hospitalier Pellegrin - Hôpital Pellegrin
Bordeaux, France
CHU de Grenoble - Hôpital Albert Michallon
Grenoble, France
Hopital Claude Huriez -CHU Lille
Lille, France
Hopital Tenon Service de nephrologie
Paris, France
CHU Saint Etienne - Hôpital Nord
Saint-Priest-en-Jarez, France
Azienda Ospedaliera Universitaria Careggi
Florence, Italy
Ospedale San Raffaele
Milan, Italy
Ospedale Borgo Roma
Verona, Italy
Radboud UMC Niimegen Nephrology
Nijmegen, Netherlands
SPZOZ Centralny Szpital Kliniczny UM w Lodzi
Lodz, Poland
Centrum Zdrowia MDM
Warsaw, Poland
Miedzyleski Szpital Specjalistyczny
Warsaw, Poland
Chungnam National University Hospital
Daejeon, South Korea
Hallym University Kangdong Sacred Heart Hospital
Seoul, South Korea
Gangnam Severance Hospital
Seoul, South Korea
The Catholic University of Korea
Seoul, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Hospital Clinic de Barcelona
Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitario Reina Sofia
Córdoba, Spain
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.